S&P 500   4,279.86 (+0.15%)
DOW   33,587.55 (-0.09%)
QQQ   356.31 (+0.59%)
AAPL   170.70 (-0.73%)
MSFT   313.71 (+0.50%)
META   299.28 (+0.11%)
GOOGL   130.70 (+1.66%)
AMZN   126.63 (+0.52%)
TSLA   241.71 (-0.99%)
NVDA   426.96 (+1.87%)
NIO   8.50 (+1.07%)
BABA   86.34 (+0.50%)
AMD   98.96 (+3.13%)
T   14.89 (-0.87%)
F   12.39 (-0.32%)
MU   68.50 (+0.82%)
CGC   0.93 (+0.30%)
GE   110.96 (+0.94%)
DIS   80.16 (+0.14%)
AMC   7.61 (-3.79%)
PFE   32.14 (-0.80%)
PYPL   57.69 (-2.10%)
NFLX   380.00 (+0.20%)
S&P 500   4,279.86 (+0.15%)
DOW   33,587.55 (-0.09%)
QQQ   356.31 (+0.59%)
AAPL   170.70 (-0.73%)
MSFT   313.71 (+0.50%)
META   299.28 (+0.11%)
GOOGL   130.70 (+1.66%)
AMZN   126.63 (+0.52%)
TSLA   241.71 (-0.99%)
NVDA   426.96 (+1.87%)
NIO   8.50 (+1.07%)
BABA   86.34 (+0.50%)
AMD   98.96 (+3.13%)
T   14.89 (-0.87%)
F   12.39 (-0.32%)
MU   68.50 (+0.82%)
CGC   0.93 (+0.30%)
GE   110.96 (+0.94%)
DIS   80.16 (+0.14%)
AMC   7.61 (-3.79%)
PFE   32.14 (-0.80%)
PYPL   57.69 (-2.10%)
NFLX   380.00 (+0.20%)
S&P 500   4,279.86 (+0.15%)
DOW   33,587.55 (-0.09%)
QQQ   356.31 (+0.59%)
AAPL   170.70 (-0.73%)
MSFT   313.71 (+0.50%)
META   299.28 (+0.11%)
GOOGL   130.70 (+1.66%)
AMZN   126.63 (+0.52%)
TSLA   241.71 (-0.99%)
NVDA   426.96 (+1.87%)
NIO   8.50 (+1.07%)
BABA   86.34 (+0.50%)
AMD   98.96 (+3.13%)
T   14.89 (-0.87%)
F   12.39 (-0.32%)
MU   68.50 (+0.82%)
CGC   0.93 (+0.30%)
GE   110.96 (+0.94%)
DIS   80.16 (+0.14%)
AMC   7.61 (-3.79%)
PFE   32.14 (-0.80%)
PYPL   57.69 (-2.10%)
NFLX   380.00 (+0.20%)
S&P 500   4,279.86 (+0.15%)
DOW   33,587.55 (-0.09%)
QQQ   356.31 (+0.59%)
AAPL   170.70 (-0.73%)
MSFT   313.71 (+0.50%)
META   299.28 (+0.11%)
GOOGL   130.70 (+1.66%)
AMZN   126.63 (+0.52%)
TSLA   241.71 (-0.99%)
NVDA   426.96 (+1.87%)
NIO   8.50 (+1.07%)
BABA   86.34 (+0.50%)
AMD   98.96 (+3.13%)
T   14.89 (-0.87%)
F   12.39 (-0.32%)
MU   68.50 (+0.82%)
CGC   0.93 (+0.30%)
GE   110.96 (+0.94%)
DIS   80.16 (+0.14%)
AMC   7.61 (-3.79%)
PFE   32.14 (-0.80%)
PYPL   57.69 (-2.10%)
NFLX   380.00 (+0.20%)
NASDAQ:VNDA

Vanda Pharmaceuticals (VNDA) Stock Forecast, Price & News

$4.59
+0.05 (+1.10%)
(As of 03:15 PM ET)
Compare
Today's Range
$4.52
$4.64
50-Day Range
$4.28
$6.53
52-Week Range
$4.15
$11.04
Volume
463,797 shs
Average Volume
765,980 shs
Market Capitalization
$263.97 million
P/E Ratio
17.00
Dividend Yield
N/A
Price Target
N/A

Vanda Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
7.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.88mentions of Vanda Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$75,009 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

249th out of 963 stocks

Pharmaceutical Preparations Industry

101st out of 451 stocks


VNDA stock logo

About Vanda Pharmaceuticals (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

VNDA Price History

VNDA Stock News Headlines

Windfall profits possible with this under-the-radar lithium stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Vanda Pharmaceuticals (NASDAQ: VNDA)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Q2 2023 Vanda Pharmaceuticals Inc Earnings Call
What Wall Street expects from Vanda Pharmaceuticals's earnings
4 Best Biotech Stocks According to POWR Ratings
Q1 2023 Vanda Pharmaceuticals Inc Earnings Call
See More Headlines
Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Company Calendar

Last Earnings
7/27/2023
Today
9/27/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VNDA
CUSIP
92165910
Employees
290
Year Founded
2002

Profitability

Net Income
$6.28 million
Pretax Margin
9.73%

Debt

Sales & Book Value

Annual Sales
$254.38 million
Cash Flow
$0.11 per share
Book Value
$9.32 per share

Miscellaneous

Free Float
53,081,000
Market Cap
$262.82 million
Optionable
Optionable
Beta
0.70

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Mihael H. Polymeropoulos M.D. (Age 63)
    Founder, Pres, CEO & Chairman of The Board
    Comp: $1.51M
  • Mr. Kevin Patrick Moran (Age 39)
    Sr. VP, CFO & Treasurer
    Comp: $660.22k
  • Mr. Timothy Williams (Age 47)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $724.38k
  • Mr. Joakim  WijkstromMr. Joakim Wijkstrom (Age 57)
    Sr. VP & Chief Marketing Officer
    Comp: $836.36k
  • Mr. Gunther Birznieks (Age 53)
    Sr. VP of Bus. Devel.
    Comp: $690.83k
  • Mr. Scott L. Howell
    Chief People Officer
  • Ms. Elizabeth Van Every
    Head of Corp. Affairs













VNDA Stock - Frequently Asked Questions

How have VNDA shares performed in 2023?

Vanda Pharmaceuticals' stock was trading at $7.39 at the beginning of the year. Since then, VNDA shares have decreased by 38.2% and is now trading at $4.57.
View the best growth stocks for 2023 here
.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 4,210,000 shares, an increase of 50.4% from the August 31st total of 2,800,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is presently 3.8 days.
View Vanda Pharmaceuticals' Short Interest
.

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our VNDA earnings forecast
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Thursday, July, 27th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.16. The biopharmaceutical company earned $46.06 million during the quarter, compared to analysts' expectations of $49 million. Vanda Pharmaceuticals had a net margin of 6.25% and a trailing twelve-month return on equity of 2.81%.

What ETFs hold Vanda Pharmaceuticals' stock?

ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), iShares U.S. Pharmaceuticals ETF (IHE),

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (18.80%), State Street Corp (7.10%), Renaissance Technologies LLC (5.41%), Goldman Sachs Group Inc. (3.66%), Dimensional Fund Advisors LP (3.39%) and Hotchkis & Wiley Capital Management LLC (2.18%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams.
View institutional ownership trends
.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $4.57.

How much money does Vanda Pharmaceuticals make?

Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $262.82 million and generates $254.38 million in revenue each year. The biopharmaceutical company earns $6.28 million in net income (profit) each year or $0.27 on an earnings per share basis.

How many employees does Vanda Pharmaceuticals have?

The company employs 290 workers across the globe.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450.

This page (NASDAQ:VNDA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -